Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

Key Points

• Insider sale: Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics for $22,317.75, reducing his direct ownership by 15.95% to 8,617 shares. He also reported three earlier sales in August and September.
• Stock and financial performance: FDMT recently traded at $15.88, near its 12-month high of $16.93, but the company reported a quarterly loss of $1.04 per share, missing estimates, and analysts expect a full-year loss.
• Analyst outlook: The stock has a consensus “Moderate Buy” rating and an average price target of $28.56, although ratings range from “Strong Buy” to “Sell.” Institutional investors and hedge funds own 99.27% of outstanding shares.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $13.65, for a total value of $22,317.75. Following the completion of the transaction, the insider directly owned 8,617 shares of the company's stock, valued at approximately $117,622.05. The trade was a 15.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Scott Bizily also recently made the following trade(s):

• On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $14.00, for a total value of $8,176.00.
• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $19,620.00.
• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total value of $19,947.00.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT traded up $0.64 during midday trading on Tuesday, reaching $15.88. 936,611 shares of the company traded hands, compared to its average volume of 831,720. The firm has a market cap of $877.21 million, a PE ratio of -6.04 and a beta of 2.74. The stock's 50-day simple moving average is $12.87 and its 200-day simple moving average is $10.90. 4D Molecular Therapeutics, Inc. has a 12 month low of $6.96 and a 12 month high of $16.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The firm had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. As a group, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group reiterated a "buy" rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Cantor Fitzgerald upgraded 4D Molecular Therapeutics from a "neutral" rating to an "overweight" rating and set a $20.00 price target on the stock in a research report on Monday, September 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. HC Wainwright reiterated a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Finally, B. Riley Financial reissued a "buy" rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $28.56.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of large investors have recently modified their holdings of the stock. Jupiter Topco LLC acquired a new position in 4D Molecular Therapeutics during the 2nd quarter worth $76,466,000. BlackRock Inc. acquired a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $60,463,000. Janus Henderson Group PLC raised its position in shares of 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company's stock worth $48,868,000 after acquiring an additional 611,276 shares during the last quarter. Trails Edge Capital Partners LP acquired a new position in shares of 4D Molecular Therapeutics during the second quarter valued at $29,631,296. Finally, Bank of America Corp DE acquired a new position in shares of 4D Molecular Therapeutics during the second quarter valued at $14,905,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.